EiRx Therapeutic PLC - Placing.

(From AFX CNF)

RNS Number:2396J EiRx Therapeutics PLC 20 September 2006 For immediate release 20 September 2006 EIRX THERAPEUTICS PLC ("EiRx" or "the Company") AGBP500,000 PLACING Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to announce that it has Placed through Seymour Pierce Ellis, 200m Eirx shares of 0.2p nominal value, at a price of 0.25p per share. The funds raised will provide the Company with additional working capital. Application will be made for the admission of these shares to trading on AIM, with Admission expected to take place on 27 September. For further information, please contact: EiRx Therapeutics plc +44 (0) 1260226529 Buchanan Communications +44 (0) 20 7466 5000 Tim Anderson / Mark Court / Mary-Jane Johnson ENDS Notes for Editors: About EiRx EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing new targeted therapies for the treatment of cancer. EiRx is headquartered in Cork, Ireland, conducts drug discovery from its laboratories in Cork and in Aberdeen, Scotland, and has an initial focus on tumours arising due to anomalous GSK/Wnt signalling, in particular breast and colorectal tumours. Since its foundation in 1999 EiRx has developed into a leader in the study of functional pathways critical to cancer cell survival and growth, with a research base encompassing apoptosis biology, translational medicine and the metabolic basis of drug resistance in tumours. Using its state-of-the-art, proprietary ALIBI(TM) platform, EiRx has gained new insights into the mechanisms underlying a cell's decision ...